SCHEMBL7736310

SCHEMBL7736310

CC(=O)NC1CCN(CC(=O)Nc2ccc(C3CCCCC3)cc2)C1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.61
HPGD P15428 2/20 0.61
NPC1 O15118 2/20 0.61
USP2 O75604 1/20 0.61
RAD52 P43351 2/20 0.52
NPSR1 Q6W5P4 1/20 0.50
DRD4 P21917 4/20 0.48
DRD2 P14416 3/20 0.48
DRD3 P35462 3/20 0.48
RORC P51449 1/20 0.47
MITF O75030 1/20 0.47
KLF5 Q13887 1/20 0.47
SLC18A3 Q16572 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
KDM4E B2RXH2 2/20 0.45
MEN1 O00255 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12460039 0.84 RAD52 (0.47) ALDH1A1NPC1RAD52NPSR1KDM4E
SCHEMBL7735984 0.82 ALDH1A1 (0.67) ALDH1A1HPGDNPC1USP2RAD52
SCHEMBL7738147 0.81 ALDH1A1 (0.81) ALDH1A1HPGDNPC1USP2RAD52
SCHEMBL7726499 0.80 ACHE (0.50) ALDH1A1HPGDNPC1MEN1KMT2A
SCHEMBL7735766 0.79 SMN1; SMN2 (0.64) ALDH1A1HPGDNPC1USP2RAD52
SCHEMBL31703375 0.78 HPGD (0.53) ALDH1A1HPGDUSP2NPSR1MEN1
SCHEMBL7738167 0.76 ALDH1A1 (1.00) ALDH1A1HPGDNPC1USP2MAPK1
SCHEMBL6243365 0.75 ALDH1A1 (0.66) ALDH1A1NPC1USP2DRD4DRD2
SCHEMBL3305614 0.75 ALDH1A1 (0.61) ALDH1A1HPGDNPC1USP2RAD52
SCHEMBL1181160 0.74 ALDH1A1 (0.59) ALDH1A1HPGDNPC1USP2RAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6410792-B1 OBESITY DISEASES BAYER CORPORATION 2002-06-25 US disclosed
US-6048900-A FOR TREATING EATING DISORDERS, INSULIN RESISTANT DIABETES, HYPERTENSION, HYPERLIPEMIA BAYER CORPORATION (US) 2000-04-11 US disclosed